Vanguard Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Vanguard Capital Management's GLUE Position: Q3 2026 in Review
Vanguard Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 1.8% in Q3 2026, buying an estimated $1.08M and bringing the position to 3,475,954 shares worth $41.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2002.
Vanguard Capital Management first reported a position in GLUE in Q1 2026 and has held it in 3 quarters since. The position peaked at $82.6M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Vanguard Capital Management held 3,475,954 shares of Monte Rosa Therapeutics worth $41.5M as of Q3 2026.
- Vanguard Capital Management bought 63,027 Monte Rosa Therapeutics shares in Q3 2026, an estimated $1.08M.
- Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2002 holding.
- Vanguard Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Monte Rosa Therapeutics position peaked at $82.6M in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.